Invasive extramammary Paget's disease (EMPD) is highly metastatic to lymph nodes and other organs, including bone, and when metastatic lesions have expanded beyond the inguinal lymph node, it is difficult to cure. In this report, we present a case of multiple metastasized, receptor activator of nuclear factor kappa-B ligand-expressing EMPD in the pelvic lymph nodes successfully cured with continuous administration of bisphosphonate risedronate sodium after intensive CyberKnife radiotherapy and docetaxel monochemotherapy. Our present case suggested the usefulness of bisphosphonates as a maintenance therapy for metastatic invasive EMPD after the intensive chemoradiotherapy.
Introduction
Extramammary Paget's disease (EMPD) is a skin adenocarcinoma that mainly occurs in the anogenital region.
1 Once Paget's cells infiltrate into the dermis, EMPD is highly metastatic to lymph nodes and other organs, including bone. 2 Meanwhile, the use of bisphosphonates (BPs) in receptor activator of nuclear factor kappa-B ligand (RANKL)-expressing apocrine-origin tumor (e.g., breast cancer, prostate cancer) has been increasing. 3,4 As we have previously reported, Paget cells in EMPD strongly express RANKL, which stimulates tumor-associated macrophages (TAMs) to recruit regulatory T cells (Tregs) in the lesional skin of EMPD. 5, 6 These reports suggested that TAMs could be a therapeutic target for the treatment of EMPD. In this report, we present a case of multiple metastasized EMPD in the pelvic lymph nodes successfully cured with continuous administration of BP risedronate sodium after intensive CyberKnife radiotherapy and docetaxel (DTX) monochemotherapy.
Case Report
A 53-year-old man presented to our institution with a 6-month history of painful erythema on his scrotum. On his initial visit, physical examination revealed a red, easy-to-bleed plaque with necrotic tissue from the right inguinal region ( Figure 1A ) to the perianal region. The skin biopsy revealed rounded cells that were devoid of intracellular bridges and large nucleus, from the epidermis to the superficial dermis. Immunohistochemical staining revealed that these tumor cells were positive for cytokeratin 7 (CK7), Periodic acideSchiff (PAS), gross cystic disease fluid protein 15 (GCDFP-15), Alcian blue, RANKL ( Figure 1B ), and matrix metalloproteinase 7 (MMP7), and negative for cytokeratin 20 (CK20). In addition, CD163 þ TAMs were detected adjacent to the Paget cells in the dermis ( Figure 1C ). From the above findings, we diagnosed this case as RANKL -expressing, invasive EMPD. We screened for a possible internal malignancy with positron emission tomographyecomputed tomography (PETeCT), which revealed significant Conflict of interests: The authors declare that they have no financial or nonfinancial conflicts of interest related to the subject matter or materials discussed in this article.enlargement of the right inguinal lymph nodes. We resected the tumor with a 3-cm surgical margin together with bilateral ingrown lymph node dissection. Then, we used immunohistochemical staining of RANKL ( Figure 1D ), MMP7 ( Figure 1E ), and CD163 ( Figure 1F ) for metastatic lymph node, which revealed that Paget's cells in the metastatic lymph nodes also expressed RANKL and MMP7, and were surrounded by CD163 þ TAMs such as skin lesions.
Additional radiotherapy after the surgical treatment was performed on the pelvic and bilateral inguinal region with a total dose of 60 Gy. Two years after the tumor excision, PETeCT revealed significant enlargement of the multiple pelvic lymph nodes around the inferior vena cava ( Figure 2A ). As the lesion adhered to the inferior vena cava and standard surgical therapy would be impractical, we used a CyberKnife. The lesion of the pelvic lymph node was irradiated with 50 Gy in 10 fractions. One month after the irradiation, the tumor mass had completely regressed ( Figure 2B ). Then, we administered DTX monthly at 40 mg/m 2 body surface area intravenously eight times, and oral administration of 17.5 mg sodium risedronate hydrate weekly for 5 years with the patient's informed consent. Five years after the CyberKnife treatment, there was no evidence of further metastasis.
Discussion
In this report, we present a case of multiple metastasized EMPD in the pelvic lymph nodes successfully cured with continuous administration of BPs risedronate sodium after intensive CyberKnife radiotherapy and DTX monochemotherapy. As a previous report suggested, invasive EMPD is highly metastatic to lymph nodes (47%), and when metastatic lesions expand beyond the inguinal lymph node and have metastasized systemically, it is difficult to cure. 
